1. Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health. 2015; 5:020415.
![crossref](/image/icon/bnr_ref_cross.gif)
2. Park HS, Choi GS, Cho JS, Kim YY. Epidemiology and current status of allergic rhinitis, asthma, and associated allergic diseases in Korea: ARIA Asia-Pacific workshop report. Asian Pac J Allergy Immunol. 2009; 27:167–171.
3. Yoo KH, Kim YS, Sheen SS, Park JH, Hwang YI, Kim SH, et al. Prevalence of chronic obstructive pulmonary disease in Korea: the fourth Korean National Health and Nutrition Examination Survey, 2008. Respirology. 2011; 16:659–665.
4. Organization for Economic Co-operation and Development. OECD.stat. Total population by sex and age [Internet]. Paris: Organization for Economic Co-operation and Development;2016. cited 2016 Aug 2. Available from:
http://stats.oecd.org/index.aspx?DataSetCode=RPOP#.
5. Soriano JB, Davis KJ, Coleman B, Visick G, Mannino D, Pride NB. The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest. 2003; 124:474–481.
6. Reddel HK, Bateman ED, Becker A, Boulet LP, Cruz AA, Drazen JM, et al. A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J. 2015; 46:622–639.
7. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013; 187:347–365.
8. Gibson PG, McDonald VM, Marks GB. Asthma in older adults. Lancet. 2010; 376:803–813.
9. Eisner MD, Anthonisen N, Coultas D, Kuenzli N, Perez-Padilla R, Postma D, et al. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010; 182:693–718.
10. Barnes PJ, Burney PG, Silverman EK, Celli BR, Vestbo J, Wedzicha JA, et al. Chronic obstructive pulmonary disease. Nat Rev Dis Primers. 2015; 1:15076.
11. van Gemert F, Kirenga B, Chavannes N, Kamya M, Luzige S, Musinguzi P, et al. Prevalence of chronic obstructive pulmonary disease and associated risk factors in Uganda (FRESH AIR Uganda): a prospective cross-sectional observational study. Lancet Glob Health. 2015; 3:e44–e51.
12. Po JY, FitzGerald JM, Carlsten C. Respiratory disease associated with solid biomass fuel exposure in rural women and children: systematic review and meta-analysis. Thorax. 2011; 66:232–239.
13. Sin DD, Miravitlles M, Mannino DM, Soriano JB, Price D, Celli BR, et al. What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion. Eur Respir J. 2016; 48:664–673.
14. Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax. 2002; 57:226–230.
15. Agusti A, Bel E, Thomas M, Vogelmeier C, Brusselle G, Holgate S, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016; 47:410–419.
16. Siddiqui SH, Guasconi A, Vestbo J, Jones P, Agusti A, Paggiaro P, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015; 192:523–525.
17. Pavord ID, Lettis S, Locantore N, Pascoe S, Jones PW, Wedzicha JA, et al. Blood eosinophils and inhaled corticosteroid/long-acting beta-2 agonist efficacy in COPD. Thorax. 2016; 71:118–125.
18. Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999-2012. JAMA. 2015; 314:1818–1831.
19. Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015; 175:827–834.
21. Soler-Cataluna JJ, Cosio B, Izquierdo JL, Lopez-Campos JL, Marin JM, Aguero R, et al. Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol. 2012; 48:331–337.
22. Cosio BG, Soriano JB, Lopez-Campos JL, Calle-Rubio M, Soler-Cataluna JJ, de-Torres JP, et al. Defining the asthma-COPD overlap syndrome in a COPD cohort. Chest. 2016; 149:45–52.
23. Shirtcliffe P, Marsh S, Travers J, Weatherall M, Beasley R. Childhood asthma and GOLD-defined chronic obstructive pulmonary disease. Intern Med J. 2012; 42:83–88.
24. Menezes AM, Montes de Oca M, Perez-Padilla R, Nadeau G, Wehrmeister FC, Lopez-Varela MV, et al. Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPD-asthma. Chest. 2014; 145:297–304.
25. Marsh SE, Travers J, Weatherall M, Williams MV, Aldington S, Shirtcliffe PM, et al. Proportional classifications of COPD phenotypes. Thorax. 2008; 63:761–767.
26. Kauppi P, Kupiainen H, Lindqvist A, Tammilehto L, Kilpelainen M, Kinnula VL, et al. Overlap syndrome of asthma and COPD predicts low quality of life. J Asthma. 2011; 48:279–285.
27. Hardin M, Silverman EK, Barr RG, Hansel NN, Schroeder JD, Make BJ, et al. The clinical features of the overlap between COPD and asthma. Respir Res. 2011; 12:127.
28. Izquierdo-Alonso JL, Rodriguez-Gonzalezmoro JM, de Lucas-Ramos P, Unzueta I, Ribera X, Anton E, et al. Prevalence and characteristics of three clinical phenotypes of chronic obstructive pulmonary disease (COPD). Respir Med. 2013; 107:724–731.
29. Johannessen A, Omenaas E, Bakke P, Gulsvik A. Incidence of GOLD-defined chronic obstructive pulmonary disease in a general adult population. Int J Tuberc Lung Dis. 2005; 9:926–932.
30. Danielsson P, Olafsdottir IS, Benediktsdottir B, Gislason T, Janson C. The prevalence of chronic obstructive pulmonary disease in Uppsala, Sweden: the Burden of Obstructive Lung Disease (BOLD) study: cross-sectional population-based study. Clin Respir J. 2012; 6:120–127.
31. Methvin JN, Mannino DM, Casey BR. COPD prevalence in southeastern Kentucky: the burden of lung disease study. Chest. 2009; 135:102–107.
32. Miravitlles M, Soriano JB, Ancochea J, Munoz L, Duran-Tauleria E, Sanchez G, et al. Characterisation of the overlap COPD-asthma phenotype: focus on physical activity and health status. Respir Med. 2013; 107:1053–1060.
33. Zhou Y, Wang C, Yao W, Chen P, Kang J, Huang S, et al. COPD in Chinese nonsmokers. Eur Respir J. 2009; 33:509–518.
34. Jyrki-Tapani K, Sovijarvi A, Lundback B. Chronic obstructive pulmonary disease in Finland: prevalence and risk factors. COPD. 2005; 2:331–339.
35. Fabbri LM, Romagnoli M, Corbetta L, Casoni G, Busljetic K, Turato G, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003; 167:418–424.
36. Rhee CK, Yoon HK, Yoo KH, Kim YS, Lee SW, Park YB, et al. Medical utilization and cost in patients with overlap syndrome of chronic obstructive pulmonary disease and asthma. COPD. 2014; 11:163–170.
37. Alshabanat A, Zafari Z, Albanyan O, Dairi M, FitzGerald JM. Asthma and COPD overlap syndrome (ACOS): a systematic review and meta analysis. PLoS One. 2015; 10:e0136065.
38. Tkacova R, Dai DL, Vonk JM, Leung JM, Hiemstra PS, van den Berge M, et al. Airway hyperresponsiveness in chronic obstructive pulmonary disease: a marker of asthma-chronic obstructive pulmonary disease overlap syndrome? J Allergy Clin Immunol. 2016; 138:1571–1579.
39. Jones RL, Noble PB, Elliot JG, James AL. Airway remodelling in COPD: it's not asthma! Respirology. 2016; 21:1347–1356.
40. Tan WC, Sin DD, Bourbeau J, Hernandez P, Chapman KR, Cowie R, et al. Characteristics of COPD in never-smokers and ever-smokers in the general population: results from the Can-COLD study. Thorax. 2015; 70:822–829.
41. Thomsen M, Nordestgaard BG, Vestbo J, Lange P. Characteristics and outcomes of chronic obstructive pulmonary disease in never smokers in Denmark: a prospective population study. Lancet Respir Med. 2013; 1:543–550.
42. de Marco R, Accordini S, Marcon A, Cerveri I, Anto JM, Gislason T, et al. Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults. Am J Respir Crit Care Med. 2011; 183:891–897.
43. James AL, Palmer LJ, Kicic E, Maxwell PS, Lagan SE, Ryan GF, et al. Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking. Am J Respir Crit Care Med. 2005; 171:109–114.
44. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med. 1998; 339:1194–1200.
45. Nielsen M, Barnes CB, Ulrik CS. Clinical characteristics of the asthma-COPD overlap syndrome: a systematic review. Int J Chron Obstruct Pulmon Dis. 2015; 10:1443–1454.
46. de Marco R, Pesce G, Marcon A, Accordini S, Antonicelli L, Bugiani M, et al. The coexistence of asthma and chronic obstructive pulmonary disease (COPD): prevalence and risk factors in young, middle-aged and elderly people from the general population. PLoS One. 2013; 8:e62985.
47. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet. 2004; 364:709–721.
48. Camp PG, Ramirez-Venegas A, Sansores RH, Alva LF, Mc-Dougall JE, Sin DD, et al. COPD phenotypes in biomass smoke-versus tobacco smoke-exposed Mexican women. Eur Respir J. 2014; 43:725–734.
49. McDonough JE, Yuan R, Suzuki M, Seyednejad N, Elliott WM, Sanchez PG, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med. 2011; 365:1567–1575.
50. Gelb AF, Yamamoto A, Verbeken EK, Nadel JA. Unraveling the pathophysiology of the asthma-COPD overlap syndrome: unsuspected mild centrilobular emphysema Is responsible for loss of lung elastic recoil in never smokers with asthma with persistent expiratory airflow limitation. Chest. 2015; 148:313–320.
51. Singh D, Kolsum U, Brightling CE, Locantore N, Agusti A, Tal-Singer R, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014; 44:1697–1700.
52. Christenson SA, Steiling K, van den Berge M, Hijazi K, Hiemstra PS, Postma DS, et al. Asthma-COPD overlap: clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015; 191:758–766.
53. Hardin M, Cho M, McDonald ML, Beaty T, Ramsdell J, Bhatt S, et al. The clinical and genetic features of COPD-asthma overlap syndrome. Eur Respir J. 2014; 44:341–350.
54. Gao Y, Zhai X, Li K, Zhang H, Wang Y, Lu Y, et al. Asthma COPD overlap syndrome on CT densitometry: a distinct phenotype from COPD. COPD. 2016; 13:471–476.
55. Sorino C, Pedone C, Scichilone N. Fifteen-year mortality of patients with asthma-COPD overlap syndrome. Eur J Intern Med. 2016; 34:72–77.
56. Lange P, Colak Y, Ingebrigtsen TS, Vestbo J, Marott JL. Long-term prognosis of asthma, chronic obstructive pulmonary disease, and asthma-chronic obstructive pulmonary disease overlap in the Copenhagen City Heart study: a prospective population-based analysis. Lancet Respir Med. 2016; 4:454–462.
57. Castiglia D, Battaglia S, Benfante A, Sorino C, Scichilone N. Pharmacological management of elderly patients with asthma-chronic obstructive pulmonary disease overlap syndrome: room for speculation? Drugs Aging. 2016; 33:375–385.
58. Lapperre TS, Snoeck-Stroband JB, Gosman MM, Jansen DF, van Schadewijk A, Thiadens HA, et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2009; 151:517–527.
59. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000; 343:1902–1909.
60. Park HY, Lee H, Koh WJ, Kim S, Jeong I, Koo HK, et al. Association of blood eosinophils and plasma periostin with FEV1 response after 3-month inhaled corticosteroid and long-acting beta2-agonist treatment in stable COPD patients. Int J Chron Obstruct Pulmon Dis. 2016; 11:23–30.
61. Pavord ID, Lettis S, Anzueto A, Barnes N. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. Lancet Respir Med. 2016; 4:731–741.
62. Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Molken MP, Beeh KM, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011; 364:1093–1103.
63. Sin DD, Tashkin D, Zhang X, Radner F, Sjobring U, Thoren A, et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet. 2009; 374:712–719.